Syros Pharmaceuticals, Inc. to Post FY2028 Earnings of $11.61 Per Share, Brookline Capital Management Forecasts (NASDAQ:SYRS)

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS - Free Report) - Stock analysts at Brookline Capital Management issued their FY2028 earnings per share (EPS) estimates for shares of Syros Pharmaceuticals in a note issued to investors on Wednesday, March 27th. Brookline Capital Management analyst L. Cann forecasts that the company will post earnings per share of $11.61 for the year. The consensus estimate for Syros Pharmaceuticals' current full-year earnings is ($4.73) per share.

Separately, StockNews.com downgraded Syros Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Tuesday, March 12th.

Syros Pharmaceuticals Stock Performance

Shares of SYRS stock traded down $0.49 on Thursday, hitting $5.35. 318,061 shares of the stock traded hands, compared to its average volume of 198,902. The company's fifty day moving average is $6.86 and its 200 day moving average is $5.06. The company has a debt-to-equity ratio of 1.09, a current ratio of 4.31 and a quick ratio of 4.31. Syros Pharmaceuticals has a 1-year low of $2.09 and a 1-year high of $8.17. The company has a market capitalization of $112.72 million, a PE ratio of -1.43 and a beta of 1.79.

Institutional Investors Weigh In On Syros Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Bain Capital Life Sciences Investors LLC increased its stake in shares of Syros Pharmaceuticals by 29.4% during the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 2,749,808 shares of the company's stock valued at $21,421,000 after acquiring an additional 625,114 shares during the period. Avidity Partners Management LP raised its stake in shares of Syros Pharmaceuticals by 5.8% in the 4th quarter. Avidity Partners Management LP now owns 1,673,538 shares of the company's stock worth $13,037,000 after buying an additional 92,396 shares in the last quarter. Blue Owl Capital Holdings LP acquired a new stake in shares of Syros Pharmaceuticals in the fourth quarter valued at $11,632,000. Point72 Asset Management L.P. bought a new position in Syros Pharmaceuticals during the fourth quarter valued at about $11,465,000. Finally, CHI Advisors LLC grew its holdings in Syros Pharmaceuticals by 69.3% during the third quarter. CHI Advisors LLC now owns 1,299,359 shares of the company's stock worth $5,119,000 after acquiring an additional 531,914 shares during the period. 91.47% of the stock is currently owned by institutional investors.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.